Neuroradiology · 2026
Core-based voxel-wise T2-FLAIR mismatch analysis for differentiation of IDH-mutant astrocytomas from oligodendrogliomas.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Erol Seyit, Baytok Ahmet, Arı Ayşe, Özer Halil, Cebeci Hakan
Аннотация
OBJECTIVE: This study aims to develop a voxel-wise quantitative framework for the T2-FLAIR mismatch signal in routine MRI scans to differentiate IDH-mutant astrocytomas from oligodendrogliomas.
METHODS: This retrospective study analyzed 43 patients with confirmed diffuse gliomas (25 astrocytomas and 18 oligodendrogliomas) using preoperative T2-weighted and FLAIR MRI. A voxel-wise log-ratio mismatch map was created, and whole-tumor regions of interest (ROIs) were defined through manual segmentations and inward tumor boundary restrictions. Five mismatch biomarkers were extracted: PositiveMismatchRatio, MeanMismatchStrength, MismatchStd, PositiveMismatchMean, and LargestMismatchClusterRatio. Group comparisons utilized the Mann-Whitney U test, and diagnostic performance was assessed through receiver operating characteristic (ROC) analysis.
RESULTS: The analysis revealed that several voxel-wise mismatch biomarkers presented significantly higher values in astrocytomas compared to oligodendrogliomas, particularly in core-restricted ROIs. The best overall performance was achieved by LargestMismatchClusterRatio in the 3-mm core ROI (AUC, 0.786; 95% CI, 0.640-0.914), followed closely by PositiveMismatchRatio in the same ROI (AUC, 0.779; 95% CI, 0.631-0.910). Threshold-based analysis showed that PositiveMismatchRatio in the 3-mm core ROI provided the strongest rule-in performance, with 60.0% sensitivity, 94.4% specificity, a positive likelihood ratio of 10.80, and a diagnostic odds ratio of 25.5. Overall, core restriction improved discrimination performance compared to whole-tumor assessments.
CONCLUSIONS: Core-based voxel-wise quantification of T2-FLAIR signal discordance showed preliminary diagnostic value for differentiating IDH-mutant astrocytomas from oligodendrogliomas, particularly as a high-specificity rule-in approach. External validation in larger multicenter cohorts is required before clinical application.
METHODS: This retrospective study analyzed 43 patients with confirmed diffuse gliomas (25 astrocytomas and 18 oligodendrogliomas) using preoperative T2-weighted and FLAIR MRI. A voxel-wise log-ratio mismatch map was created, and whole-tumor regions of interest (ROIs) were defined through manual segmentations and inward tumor boundary restrictions. Five mismatch biomarkers were extracted: PositiveMismatchRatio, MeanMismatchStrength, MismatchStd, PositiveMismatchMean, and LargestMismatchClusterRatio. Group comparisons utilized the Mann-Whitney U test, and diagnostic performance was assessed through receiver operating characteristic (ROC) analysis.
RESULTS: The analysis revealed that several voxel-wise mismatch biomarkers presented significantly higher values in astrocytomas compared to oligodendrogliomas, particularly in core-restricted ROIs. The best overall performance was achieved by LargestMismatchClusterRatio in the 3-mm core ROI (AUC, 0.786; 95% CI, 0.640-0.914), followed closely by PositiveMismatchRatio in the same ROI (AUC, 0.779; 95% CI, 0.631-0.910). Threshold-based analysis showed that PositiveMismatchRatio in the 3-mm core ROI provided the strongest rule-in performance, with 60.0% sensitivity, 94.4% specificity, a positive likelihood ratio of 10.80, and a diagnostic odds ratio of 25.5. Overall, core restriction improved discrimination performance compared to whole-tumor assessments.
CONCLUSIONS: Core-based voxel-wise quantification of T2-FLAIR signal discordance showed preliminary diagnostic value for differentiating IDH-mutant astrocytomas from oligodendrogliomas, particularly as a high-specificity rule-in approach. External validation in larger multicenter cohorts is required before clinical application.